TS

Thaduri Srivani

Active Director Director DIN 02658723
DIN 02658723 First appointment May 2009 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 1 historical roles
Total affiliations 5 Since May 2009
Shareholding value •••• Premium profile

About Thaduri Srivani

Data last updated:

Thaduri Srivani is a Director at Stereokem Private Limited (since 2013), Director at Stereokem Pharmaceuticals Private Limited (since 2012) and Director at Genotech Pharmaceuticals Private Limited (since 2021), and holds 1 more current directorship. The companies operate in Pharma. The 4 current companies with reported revenue have a combined latest revenue of ₹20.49 Cr; the largest is Stereokem Private Limited at ₹13.93 Cr (FY 2024). Earlier, Thaduri Srivani was a Director at Stereokem India Private Limited (from 2013).

DIN 02658723
Primary Designation Director
Industry Pharma
First Appointment 28 May 2009
Oldest Company Age 18 yrs
Largest company Stereokem Private Limited · ₹13.93 Cr (FY 2024)
Combined revenue ₹20.49 Cr across 4 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Stereokem Private Limited U24232TG2009PTC064427
Director16 Feb 20132009₹13.93 Cr (FY 2024)Active
Director26 Dec 20122012₹6.31 Cr (FY 2023)Active
Director25 May 20212010₹25.4 Lakh (FY 2025)Active
Jyostna Laboratories Private Limited U74900TG2008PTC061233
Director28 May 20092008₹15,000 (FY 2024)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Stereokem India Private Limited U24233TG2013PTC087843
Director23 May 20132013Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Stereokem Pharmaceuticals Private Limited
Stereokem Private Limited
Genotech Pharmaceuticals Private Limited
Stereokem India Private Limited
Premium access

Shareholding and investment profile for Thaduri Srivani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Thaduri Srivani

Thaduri Srivani currently holds 4 directorships: Stereokem Private Limited (Director, since 16 Feb 2013, revenue ₹13.93 Cr (FY 2024)); Stereokem Pharmaceuticals Private Limited (Director, since 26 Dec 2012, revenue ₹6.31 Cr (FY 2023)); Genotech Pharmaceuticals Private Limited (Director, since 25 May 2021, revenue ₹25.4 Lakh (FY 2025)); Jyostna Laboratories Private Limited (Director, since 28 May 2009, revenue ₹15,000 (FY 2024)).

Thaduri Srivani was first appointed on 28 May 2009 as Director at Jyostna Laboratories Private Limited. The most recent appointment on record is 25 May 2021 at Genotech Pharmaceuticals Private Limited.

The 4 current companies of Thaduri Srivani that report revenue have a combined latest revenue of ₹20.49 Cr: Stereokem Private Limited ₹13.93 Cr (FY 2024); Stereokem Pharmaceuticals Private Limited ₹6.31 Cr (FY 2023); Genotech Pharmaceuticals Private Limited ₹25.4 Lakh (FY 2025); Jyostna Laboratories Private Limited ₹15,000 (FY 2024).

Thaduri Srivani held 1 earlier board appointment: Stereokem India Private Limited (Director, from 23 May 2013).

The current boards of Thaduri Srivani's companies include Venkateshwar Thaduri Kumar (Stereokem Private Limited), Venugopala Bandi Rao (Stereokem Private Limited), Narayana Varma Vegiraju (Stereokem Pharmaceuticals Private Limited), Murari Rajakumari (Genotech Pharmaceuticals Private Limited), Ravi Kumar Pericherla (Genotech Pharmaceuticals Private Limited), Suryanarayana Kolagani (Genotech Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available